Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA.
Med Decis Making. 2024 Jan;44(1):53-63. doi: 10.1177/0272989X231208673. Epub 2023 Nov 22.
The test tradeoff curve helps investigators decide if collecting data for risk prediction is worthwhile when risk prediction is used for treatment decisions. At a given benefit-cost ratio (the number of false-positive predictions one would trade for a true positive prediction) or risk threshold (the probability of developing disease at indifference between treatment and no treatment), the test tradeoff is the minimum number of data collections per true positive to yield a positive maximum expected utility of risk prediction. For example, a test tradeoff of 3,000 invasive tests per true-positive prediction of cancer may suggest that risk prediction is not worthwhile. A test tradeoff curve plots test tradeoff versus benefit-cost ratio or risk threshold. The test tradeoff curve evaluates risk prediction at the optimal risk score cutpoint for treatment, which is the cutpoint of the risk score (the estimated risk of developing disease) that maximizes the expected utility of risk prediction when the receiver-operating characteristic (ROC) curve is concave.
Previous methods for estimating the test tradeoff required grouping risk scores. Using individual risk scores, the new method estimates a concave ROC curve by constructing a concave envelope of ROC points, taking a slope-based moving average, minimizing a sum of squared errors, and connecting successive ROC points with line segments.
The estimated concave ROC curve yields an estimated test tradeoff curve. Analyses of 2 synthetic data sets illustrate the method.
Estimating the test tradeoff curve based on individual risk scores is straightforward to implement and more appealing than previous estimation methods that required grouping risk scores.
The test tradeoff curve helps investigators decide if collecting data for risk prediction is worthwhile when risk prediction is used for treatment decisions.At a given benefit-cost ratio or risk threshold, the test tradeoff is the minimum number of data collections per true positive to yield a positive maximum expected utility of risk prediction.Unlike previous estimation methods that grouped risk scores, the method uses individual risk scores to estimate a concave ROC curve, which yields an estimated test tradeoff curve.
当风险预测用于治疗决策时,测试权衡曲线可以帮助研究人员决定收集风险预测数据是否值得。在给定的收益-成本比(每一个假阳性预测需要交换的真阳性预测数量)或风险阈值(在治疗和不治疗之间无差异时发病的概率)下,测试权衡是每一个真阳性预测产生阳性最大风险预测期望效用所需的最小数据采集量。例如,癌症阳性预测每 3000 个测试的测试权衡可能表明风险预测的价值不大。测试权衡曲线将测试权衡与收益-成本比或风险阈值联系起来。测试权衡曲线在治疗的最佳风险评分切点处评估风险预测,切点是风险评分(发病风险的估计值)的切点,在接收器操作特性(ROC)曲线为凹形时,最大程度地提高了风险预测的期望效用。
以前估计测试权衡的方法需要对风险评分进行分组。新方法使用个体风险评分,通过构建 ROC 点的凹包络、采用基于斜率的移动平均、最小化平方和误差、以及用线段连接连续的 ROC 点,估计凹形 ROC 曲线。
估计的凹形 ROC 曲线产生了估计的测试权衡曲线。对两个合成数据集的分析说明了该方法。
基于个体风险评分估计测试权衡曲线的方法实施起来简单明了,并且比以前需要对风险评分进行分组的估计方法更有吸引力。
测试权衡曲线可以帮助研究人员决定在使用风险预测进行治疗决策时,收集风险预测数据是否值得。在给定的收益-成本比或风险阈值下,测试权衡是每一个真阳性预测产生阳性最大风险预测期望效用所需的最小数据采集量。与以前分组风险评分的估计方法不同,该方法使用个体风险评分来估计凹形 ROC 曲线,从而产生估计的测试权衡曲线。